Replies to post #209058 on NorthWest Biotherapeutics Inc (NWBO)

[CogDiss 1188X]

Nice detail around IDH and implications for treatment - thanks Flipper.

[sentiment_stocks]

I think IDH has probably been measured in the Phase III trial by now, because LL measured it in earlier DCVax-Brain trials she discussed.

Agreed. I would think they have too.

The plateau Dr. Stupp discusses for idh-1mutated only adds a few more (perhaps four to six) median months (aka: total of 27 months mOS).

I was thinking he meant those who were psPD due to chem/rad who then also turned out to be lucky enough live significantly longer. Not all psPD live past 30 to 36 months. In fact, in the Brandes trial, out of 32 psPD patients, 34% (11 out of 32) were unmethylated, and we know they don't do particularly well with chem/rad. But it's thought that it's usually a psPD patient that has a chance to survive longer. And it's possible that with DCVax-L, they may actually beat the GBM.

I also wanted to point out Stupps' comment, though reluctant (unbelievable, you'd think he'd be pleased) that "maybe tumors react differently to immunotherapy." lol.